曲奥舒凡在儿童造血干细胞移植患者中的群体药代动力学
多中心研究纳入91例接受3天累积剂量30、36或42 g/m2曲奥舒凡的儿童造血干细胞移植患者,建立二室群体药代动力学模型,发现体重(异速生长)与成熟函数显著影响清除率,4岁时清除率达成人值的90%,并提出基于模型的目标暴露1650 mg*h/L给药表及3点有限采样策略。
要点
- 体重异速生长与成熟函数是曲奥舒凡清除率的显著预测因素
- 4岁时曲奥舒凡清除率达到成人值的90%
- 输注开始后1.5、4、7小时的3点有限采样可准确估算暴露
核心结论
- 研究建立了儿童造血干细胞移植患者的曲奥舒凡群体药代动力学模型,并开发了可准确估算暴露的3点有限采样模型。
研究设计与样本
- 多中心研究,纳入91例接受3天累积剂量30、36或42 g/m2曲奥舒凡的儿童患者,建立群体药代动力学模型;另用28例患者数据开发有限采样模型。
主要发现
- 二室模型加一级消除最能描述数据;体重(异速生长)与成熟函数是曲奥舒凡清除率的显著预测因素;清除率在出生后4年达到成人值的90%。
关键数值与推荐
- 基于模型给出针对不同体重和年龄组的给药表,目标暴露为1650 mg*h/L(群体中位数);输注开始后1.5、4、7小时取样为最佳有限采样策略。
临床怎么用
- 可依据体重和年龄的模型给药表设定曲奥舒凡剂量,并用输注开始后1.5、4、7小时的3点采样进行暴露监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Treosulfan is an alkylating agent increasingly used prior to haematopoietic stem cell transplantation. The aim of this study was to develop a population pharmacokinetic (PK) model of treosulfan in paediatric haematopoietic stem cell transplantation recipients and to explore the effect of potential covariates on treosulfan PK. Also, a limited sampling model (LSM) will be developed to accurately predict treosulfan exposure suitable for a therapeutic drug monitoring setting. METHODS: In this multicentre study, 91 patients, receiving a total dose of 30, 36 or 42 g/m2 treosulfan, administered over 3 consecutive days, were enrolled. A population PK model was developed and demographic factors, as well as laboratory parameters, were included as potential covariates. In addition, a LSM was developed using data from 28 patients. RESULTS: A 2-compartment model with first order elimination best described the data. Bodyweight with allometric scaling and maturation function were identified as significant predictors of treosulfan clearance. Treosulfan clearance reaches 90% of adult values at 4 postnatal years. A model-based dosing table is presented to target an exposure of 1650 mg*h/L (population median) for different weight and age groups. Samples taken at 1.5, 4 and 7 hours after start of infusion resulted in the best limited sampling strategy. CONCLUSIONS: This study provides a treosulfan population PK model in children and captures the developmental changes in clearance. A 3-point LSM allows for accurate and precise estimation of treosulfan exposure.
引用
- van der Stoep MYEC, Zwaveling J, Bertaina A, et al. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation. Br J Clin Pharmacol. 2019. PMID: 31144349. doi:10.1111/bcp.13995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。